Olympiad Research LP Acquires New Shares in Hims & Hers Health, Inc. (NYSE:HIMS)

Olympiad Research LP acquired a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 14,242 shares of the company’s stock, valued at approximately $262,000.

A number of other large investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in Hims & Hers Health by 1.0% in the first quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock valued at $221,379,000 after acquiring an additional 136,907 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Hims & Hers Health by 113.1% in the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after acquiring an additional 3,205,108 shares during the last quarter. Farallon Capital Management LLC lifted its holdings in Hims & Hers Health by 3,890.5% in the first quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after acquiring an additional 1,634,000 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Hims & Hers Health by 67.5% in the second quarter. Bank of New York Mellon Corp now owns 678,602 shares of the company’s stock valued at $13,701,000 after acquiring an additional 273,473 shares during the last quarter. Finally, M&G Plc acquired a new position in Hims & Hers Health in the first quarter valued at approximately $8,232,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total value of $2,750,209.28. Following the completion of the transaction, the chief executive officer now owns 33,502 shares in the company, valued at $487,789.12. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 15,000 shares of the company’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $22.07, for a total value of $331,050.00. Following the completion of the transaction, the insider now owns 196,941 shares in the company, valued at $4,346,487.87. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the completion of the transaction, the chief executive officer now owns 33,502 shares of the company’s stock, valued at $487,789.12. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 854,547 shares of company stock worth $15,987,230. Corporate insiders own 17.71% of the company’s stock.

Analyst Ratings Changes

HIMS has been the topic of a number of recent analyst reports. Needham & Company LLC assumed coverage on Hims & Hers Health in a report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price objective on the stock. Bank of America boosted their target price on Hims & Hers Health from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Canaccord Genuity Group boosted their target price on Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Piper Sandler reissued a “neutral” rating and issued a $21.00 target price (up previously from $18.00) on shares of Hims & Hers Health in a research report on Tuesday. Eight equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health presently has an average rating of “Moderate Buy” and a consensus price target of $21.00.

Hims & Hers Health Trading Up 0.9 %

Shares of HIMS stock opened at $23.62 on Friday. The firm has a fifty day moving average price of $18.40 and a 200 day moving average price of $18.29. The company has a market cap of $5.07 billion, a P/E ratio of 54.80 and a beta of 1.06. Hims & Hers Health, Inc. has a 12 month low of $6.58 and a 12 month high of $25.74.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The firm had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 11.67%. The company’s revenue was up 77.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.04) earnings per share. On average, equities analysts forecast that Hims & Hers Health, Inc. will post 0.22 EPS for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.